Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
129M shares
52-week range
$7.29 – $19.25
81% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Cost of revenue | $41.4M | $0 | $0 | $1.1M | $5.7M | $14.1M | $28.2M | $32.7M |
| Gross profit | −$40.9M | $318.0K | $50.1M | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M |
| Gross margin | -8837.8% | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| R&D | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M |
| Operating income | −$56.2M | −$90.9M | −$104.3M | −$180.7M | −$111.5M | −$91.7M | −$4.7M | $104.9M |
| EBITDA | −$53.9M | −$89.8M | −$102.9M | −$177.4M | −$103.6M | −$63.0M | $31.7M | $127.8M |
| Net income | −$64.1M | −$88.4M | −$102.7M | −$181.0M | −$108.2M | −$78.0M | $5.8M | $287.2M |
| Net margin | -13848.8% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (diluted) | -0.76 | -1.33 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $326M | $0.96 | $0.76–$1.13 | 4 |
| 2027 | $388M | $1.24 | $0.78–$1.68 | 4 |
| 2028 | $473M | $1.80 | $0.59–$3.20 | 4 |
| 2029 | $494M | $1.71 | $1.59–$1.89 | 2 |
Forward consensus · source: Financial Modeling Prep
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
www.auriniapharma.comNo one on the platform currently holds AUPH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,663,835 | $24.7M |
No one on the platform has traded AUPH yet.
| $2.1B |
| — |
| IMCRImmunocore Holdings plc | $31.93 | +4.96% | $1.6B | — |
| JANXJanux Therapeutics, Inc. | $15.61 | +1.83% | $952M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 9.9× sales vs its 7.6× historical median P/S.
Fair value ≈ $13.02 · price $16.97 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AUPH Hahaha C'mon shorty you're way too obvious in wanting our shares. I have to thank you, though, for depressing the sp down to 4/5 so many could lower our average, and you will pay for it. Just a matter of time!
View on StockTwits ↗$AUPH I guess we're still just a little bitch....
View on StockTwits ↗$AUPH M are we absolutely sure pig is not still in charge?
View on StockTwits ↗$AUPH Something huge awaits us in the next few hours, stay tuned...
View on StockTwits ↗$AUPH Bored. Gonna back burner this again. Doesn’t look like Tang wants to sell before Q2! Oh well…. 🤷♀️
View on StockTwits ↗$AUPH never OWN this. TRADE it only. Easy two day swing from 16.20 - 17.24. 1,000 shares. Thanks for the profits!
View on StockTwits ↗$AUPH Minor update on generics case: "Mon 06/29 11:01 PM LETTER ORDER re71 extending deadlines and adjourning the status conference scheduled for June 30th, which will now take place on September 3, 2026, at 10:00 am. Signed by Magistrate Judge Andre M. Espinosa on 6/29/2026" This is a prep for the proceedings which according to my est. will start Q4/Q1 27, most infringement cases are settled before the start.
View on StockTwits ↗$AUPH Volume very meager at 805K. Excellent time to turn it up last 2 hours....
View on StockTwits ↗$AUPH She's locked down around 17.20ish. We need bidders for next leg up!
View on StockTwits ↗$AUPH waiting for the big boys to start shorting the hell outa bio indexes ....they running hot
View on StockTwits ↗$AUPH Tang is not going to "fry" the shorts. If you think that, you have no understanding of how this works. Patience.
View on StockTwits ↗$AUPH needs to close above 17.38 to generate a buy signal to confirm uptrend..
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.